New CSO appointed at Nimbus Therapeutics

Nimbus Therapeutics has appointed Dr. Peter Tummino, Ph.D., to Chief Scientific Officer. Dr. Tummino has more than 25 years’ experience in drug discovery across a range of therapeutic areas, most recently in his role as Vice President and Global Head of Lead Discovery in Discovery Sciences at Janssen, and before that through his multiple leadership roles at GlaxoSmithKline, including Head of Biology for the Cancer Epigenetics Discovery Performance Unit.
Dr. Tummino said: “I’m excited to dive in and get to work alongside Nimbus’ fantastic team of scientists and collaborators, with their remarkable history of successfully applying computational approaches to discover novel medicines and to advance these medicines to patients. I look forward to continuing this momentum and furthering our efforts into exciting new areas of medicine.”
Jeb Keiper, President and CEO at Nimbus, said: “Peter has an impressive track record of success in discovering and developing new medicines for patients, and we are thrilled to welcome him to our team. He has successfully built and led diverse teams of scientists, and has deep experience applying computational and other technologies across the R&D spectrum. Peter will help us write the next chapter of Nimbus, as we drive our Tyk2 inhibitor toward the clinic for autoimmune diseases and as we expand both the depth and breadth of our portfolio of programs across highly sought-after targets in metabolic disease, cancer and immune-inflammatory disorders.”